Genticel has announced that not one but two milestones have been achieved in the development of its products,  which focus on immunotherapies for cancers caused by the human papillomavirus.

genticel_roche_gtl001_gtl002_hpv_cancerGenticel is developing  GTL001 (named ProCervix in Europe) to answer an unmet medical need – the eradication of the virus HPV 16 or 18 (high-risk types that can cause cancer) for an infected body.

So far, the vaccines available for this disease are preventive vaccines, not for treating a carrier. The company estimates that over 93 million women are currently infected by those two strains!

ADVERTISEMENT

The first milestone achieved by Genticel is that the company will be able to use the Roche Molecular Systems’ Cobas 4800 test. This worldwide-available test could be used for the recruitment and post-treatment analysis of patients in the planned Phase III program of GTL001. The test efficiency was confirmed on samples from Phase II. Results were equivalent to those generated by a clinical laboratory test.

genticel_hpv_16_18_cancer_glt001

GTL001 is a first-in-class therapeutic vaccine based on adenylate cyclase (CyaA) vaccine carriers with antigens for HPV 16 and 18. (Source: Genticel)

This is also an achievement for Roche, which confirms its leading position as a developer of diagnostics.

Besides this, the stability studies have demonstrated a 5-year shelf life – the maximum time during which it can be kept without undergoing changes in chemical structure and properties. This is a terrific result, regarding the preventive vaccines Gardasil‘s shelf life is 3 years and Cervarix‘s is 4.

So these are two good pieces of news for the company, especially after its stock price drop (43%) in January. Since this last release, stocks remain relatively stable. Not a surprise, as no majors outcomes come out of this one.

genticel_stock_roche_phaseIII

No major changes in stock price in the last month (top), after a big drop that started end of January (bottom). (Source: Google Finance)

Something that could help the finance is that Genticel will also present today its results regarding GLT001 clinical trials (at the Eurogin 2016 Congress). It was the primary outcomes of Phase II studies, which were optimistically presented but at the end disappointing (primary endpoint only 10% better than placebo!), that caused the drop.

Those trials have been extended, and results of the 12-month analysis will be presented. If they are designing a Phase III, the news should be good!

During this congress, the company will also present the preclinical proof of concept of GTL002, which targets 6 strains of the virus (representing 85% of the infection). That could be useful to 158 millions of infected patients.

I’m curious to see how these new milestones may impact the company’s results and if the stock will finally go up again.


Feature Image Credit: French Alps (CC 2.0 Capucine Prevots)
Previous post

Apogenix's lead Candidate has more than one Trick up its Sleeve

Next post

BioArt: Stelarc is Beating the 'Obsolete Human Body' with MedTech

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.